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Abstract 
           In selected patients with atrial fibrillation and severe symptoms, non-pharmacological 
treatment   may   be   an   alternative   or   supplement   to   drug   therapy.   Atrioventricular   nodal 
radiofrequency ablation (requires pacemaker implantation), or atrial pacing for sick sinus 
syndrome, are established treatment modalities. All other non-pharmacological therapies for 
atrial fibrillation are still experimental. After the Maze operation, atrial depolarization has to 
follow one specific path determined by surgical scars in the myocardium. This prevents new 
episodes of atrial fibrillation, but at a cost of perioperative morbidity and mortality. Catheter-
based   "Maze-like"   radiofrequency   ablation   is   technically   difficult,   and   thrombo-embolic 
complications may occur. Paroxysmal atrial fibrillation sometimes is initiated by spontaneous 
depolarizations in a pulmonary vein inlet. Radio frequency ablation against such focal activity 
has been reported with high therapeutic success, but the results await confirmation from several 
centres. For ventricular rate control, most electrophysiologists presently prefer ablation to induce 
a complete atrioventricular conduction block (with pacemaker) rather than trying to modify 
conduction by incomplete block. Atrial or dual chamber pacing may prevent atrial fibrillation 
induced by bradycardia. It remains to confirm that biatrial or multisite right atrial pacing 
prevents atrial fibrillation more efficiently than ordinary right atrial pacing. An atrial defibrillator 
is able to diagnose and convert atrial fibrillation. The equipment is expensive, and therapy 
without sedation may be unpleasant beyond tolerability.
           Atrial fibrillation is the most frequent sustained arrhythmia of clinical significance. The 
prevalence of chronic atrial fibrillation is about 0,5-1% 1. It is rarely seen before the age of 50. 
However, Framingham data show a marked increase of atrial fibrillation by increasing age, 
approaching 10% in octogenarians (Table 1) 2.                                                                   
           Atrial fibrillation may be paroxysmal or chronic. The chronic form may develop after 
several reversible episodes, or may occur primarily. An episode of atrial fibrillation is defined as 
chronic if, somewhat arbitrarily, it is still present after seven days 3. An attack that has not 
terminated within 48 hours is termed persistent atrial fibrillation. Pharmacological or electrical 
conversion is then usually necessary to re-establish sinus rhythm. 3                                            . 
         Atrial fibrillation may occur due to reversible factors such as alcohol ingestion, hyper­
thyroidism, or pulmonary embolism. In 70-80% of patients, atrial fibrillation is associated with 
organic heart disorders exemplified by coronary heart disease, hypertension with left ventricular 
hypertrophy, valve disease, or congenital heart defects. The number of patients with primary 
atrial fibrillation (lone fibrillation) decreases as more sophisticated diagnostic procedures are 
performed to expose underlying disease. Similarly, lone fibrillation is rare in elderly because 
subclinical heart disease proceeds and become manifest 3.   
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Table 1: Number of cases with atrial fibrillation per 100 persons examined in the 
Framingham study 2. 
Symptoms and clinical findings                                                                                             
            Atrial fibrillation causes irregular and often rapid heart rate leading to palpitations, 
dyspnoea and asthenia. Hemodynamic function is impaired both at rest and during physical 
activity. The risk of cerebrovascular insults increases 2. Thromboembolic complications are most 
frequently seen immediately after atrial fibrillation has started, during the first year of chronic 
atrial fibrillation, or early after conversion to sinus rhythm 3. Several surveys show that cardiac 
as well as total mortality in patients with atrial fibrillation is doubled compared to sex and age-
adjusted groups in sinus rhythm 4. A major part of this increased risk is, however, attributable to 
underlying structural heart disease. Lone atrial fibrillation confers little risk, at least in persons 
below 60 years of age 5. 
Electrophysiologic substrate                                                                                                 
           The pathophysiological mechanism of paroxysmal and chronic atrial fibrillation is only 
partly understood. However, there is general agreement that the following factors contribute: 
Shortened refractory period, regional variations of refractoriness (dispersion of repolarization) 
and conduction velocity, and increased ectopic activity.                                                          
          Gordon Moe described the substrate of atrial fibrillation as a continuous activation of the 
atrial myocardium by several reentry circles that are not anatomically fixed, but spread and 
mingle   in  a  seemingly  chaotic   pattern  6.   The  theoretical  length  of   each  reentry   circle 
("wavelength" = conduction velocity x refractory period) gives an expression of the minimal 
circumference each depolarization must travel to avoid that the electrical impulse reaches its 
origin before this is again excitable. When refractoriness is short and conduction velocity is 
slow, wavelength is also short. Thus, several reentry circles may exist simultaneously in the 
atria. Five or six reentry circles are associated with stable atrial fibrillation, while a situation with 
fewer reentry circles either converts to sinus rhythm, or degenerates into more reentry circles 7.    
         During the first hours to days of an attack of atrial fibrillation, electrophysiologic 
remodelling with gradual shortening of the refractory period has been found 8 . This implies 
stabilisation of the atrial fibrillation. Allessie and co-workers thus formed the thesis "Atrial 
fibrillation begets atrial fibrillation"  8  .                                                                                               
         An atrial premature or escape beat may induce atrial fibrillation due to a "P-on-T-
phenomenon". Some patients show frequent monomorphic extrasystoles, either singly or in long 
series. The origin may be found in the pulmonary vein inlets at a variable distance from the left 
atrium 9. It is conceivable that electrical impulses from this focus (mother rotor) may induce 
chaotic activation of the atria due to interaction with anatomical and/or functional barriers that 
leads to fragmentation of the depolarisation front (daughter wavelets) 10. It is not yet known how 
many patients really suffer from such focal atrial fibrillation. Small studies indicate 20% of 
primary atrial fibrillation 11, others suggest 30-40% of all paroxysmal atrial fibrillation .
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Pharmacological therapy                                                                                                        
           Most patients with atrial fibrillation are still treated pharmacologically. Antiarrhythmic 
therapy may serve one of three intentions: To convert atrial fibrillation into sinus rhythm, to 
prevent recurrence after cardioversion, or to achieve rate control in patients with permanent atrial 
fibrillation. Additionally, anticoagulation or antithrombotic therapy is indicated in several 
patients to prevent thromboembolic complications 12, 13.                                                         
           Paroxysmal atrial fibrillation frequently converts spontaneously if time is allowed to pass. 
In a study comparing different antiarrhythmic therapies, 76% of patients in the placebo group 
were in sinus rhythm within 48 hours 14. Pharmacological conversion of atrial fibrillation may be 
achieved by flecainide (conversion rate for intravenous treatment: 59-93%15 ). It remains to be 
seen which role the new class III-agents (dofetilide, ibutilide) will get. Sotalol has a limited 
conversion rate, but may be used similar to flecainide to prevent recurrence 16.                  
         Kinidine has a well documented effect both concerning cardioversion and prophylaxis, but 
its use has been limited by side effects (diarrhoea and proarrhythmia). A classical meta-analysis 
showed that while only 25% of placebo treated patients were in sinus rhythm one year after 
electroconversion of atrial fibrillation, kinidine increased this fraction to 50% 17. Newer drugs 
have not shown superior antiarrhythmic effect, but they are better tolerated. It is difficult to 
compare the prophylactic effect of different drugs between different studies, because inclusion 
criteria and duration of the arrhythmia may differ. Somewhat simplified, only 30-60% of patients 
will still be in sinus rhythm one year after a successful cardioversion, despite the use of drugs 
like flecainide, sotalol or amiodarone. Amiodarone both in studies and in daily clinic mostly has 
been reserved for resistant cases where the other drugs have failed.                                 
         Among patients with permanent atrial fibrillation, the therapeutic goal may be limited to 
rate control. Digoxin, b-blockers, verapamil or diltiazem are frequently prescribed. Digoxin may 
be combined with one of the others. 
Non-pharmacological therapy                                                                                   
            The   interest   for   non-pharmacological   therapy   has   emerged   due   to   the   limited 
antiarrhythmic and frequent proarrhythmic effects of drugs. Thus, reasons for choosing non-
pharmacological therapy may be paroxysmal atrial fibrillation with very frequent attacks and 
severe symptoms, chronic atrial fibrillation without adequate rate control leaving the patient at 
risk of developing tachycardiomyopathy, or patients who experience intolerable side effects of 
otherwise   effective   drug   therapy.   Additionally,   in   some   patients   with   severe   diastolic 
dysfunction due to for example left ventricular hypertrophy, the hemodynamic function may be 
grossly impaired if the driving force of the atrial systole disappears.                                
           Non-pharmacological therapy includes several different treatment modalities ( Table 2 ). 
With the exceptions of radiofrequency ablation of the atrioventricular node (with pacemaker 
implantation), and atrial pacing in sick-sinus syndrome, all non-pharmacological therapy of atrial 
fibrillation is still experimental.  
Surgical treatment                                                                                                                   
           Giraudon and co-workers in 1985 described the "corridor procedure", in which the right 
and left atrial free walls were isolated from the interatrial septum 18 . Rate control was achieved 
because the ventricles were controlled by the sinus node, but atrial myocardium continued to 
fibrillate. The risk of thromboembolic episodes therefore was unchanged. Today, this method 
has only historical interest.                                                                                                   
          The Maze procedure is performed by isolating the atrial appendages and cutting the atrial 
walls in a specific pattern ( Fig. 1 )19. Thereby, the depolarization wave front is forced to follow 
one specific path from the sinus node to the atrioventricular node, and thus the atrial contraction 
will be organised. Reentry will not be possible, because the area of remaining continuous atrial 
myocardium is too small compared to the "wavelength" (see above) in atrial fibrillation20 .  After 
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the first publication, the pattern of incisions in the right atrium has been slightly modified to 
avoid injury to the sinus node artery leading to sinus node dysfunction postoperatively (Maze II 
and III). Cox found that 98% of his patients achieved atrioventricular synchronicity and 
mechanical atrial contraction, and that 60% showed acceptable chronotropic function of the 
sinus node. After Maze III surgery in patients where the sinus node function was documented to 
be normal preoperatively, less than 1% needed a pacemaker 21. However, other authors have 
found that particularly the left atrial function will remain somewhat reduced compared to control 
patients. Larger patient cohorts and longer observation periods are needed to estimate any effect 
on thromboembolic episodes.                                                                                        
           A Maze operation implies major heart surgery with an expected perioperative mortality of 
1-2%. If the operation is performed in connection with valve surgery, one must expect about 70 
minutes prolongation of the time spent on heart-lung machine. To shorten this time, some 
surgeons prefer to use cryoablation or radiofrequency ablation by a handheld probe instead of 
surgical incisions. Postoperatively, fluid retention is frequently observed, probably due to the 
absence   of   atrial   natriuretic   peptide.   Several   centres   prefer   the   Maze   operation   before 
radiofrequency ablation of the atrioventricular node.   
Table 2: Various non-pharmacological treatment modalities for atrial fibrillation 
Radiofrequency ablation 
             By delivering high-frequency (radiofrequency) alternating current through ablation 
catheters, it is possible to create small lesions inside the heart exactly at the anatomical substrate 
of various arrhythmias. This method may be curative for patients with atrioventricular reentry 
(overt   or   concealed   Wolff-Parkinson-White   syndrome)   or   atrioventricular   nodal   reentry 
tachycardias. Today, more than 90% success rate may be achieved, with few complications 22. 
Atrial fibrillation in patients with Wolf-Parkinson-White-syndrome may be dangerous, because 
an accessory pathway with short refractory period causes very fast ventricular rate (pre-excited 
atrial fibrillation). If this accessory pathway is ablated, not only the atrioventricular reentry 
disappears, but also the risk of new episodes of atrial fibrillation has been shown to decrease. 
Similarly, atrioventricular nodal tachycardia may in some patients cause atrial fibrillation, and 
this may be prevented by "slow-pathway" ablation. 
Except from these examples of arrhythmia-induced atrial fibrillation, radiofrequency ablation of 
atrial fibrillation is still limited. Ablation of the AV node to induce complete block and leave the 
patient pacemaker-dependant, is a purely palliative treatment. Some electrophysiologists try to 
modify atrioventricular conduction without inducing complete block. Research has partly aimed 
at developing a catheter-based "Maze-like" procedure, partly at revealing the pathophysiological 
mechanism of atrial fibrillation and potentially perform focal ablation. 
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 Fig. 1 Schematic drawing of the right and left 
atria viewed from behind (below) or in front 
(above),   with   an   indication   of   the   surgical 
incisions   that   are   created   during   Maze   III 
operation.   Compared   to   the   original   Maze 
procedure, the incisions in the right atrium are 
slightly modified to avoid damage to the blood 
supply of the sinus node 42.  
Fig. 2  Schematic drawing of the right atrium 
and the three ablation lines posteriorly (1), 
horizontally   on   the   lateral   wall   (2),   and 
anteriorly (3) that were described in the first 
case published about curative treatment of atrial 
fibrillation by radiofrequency ablation28. This 
patient previously had been subjected to an 
inferior   caval   vein-tricuspid   valve   isthmus 
ablation due to atrial flutter.  
Induction of complete atrioventricular block 
            Historically, direct current ablation of the bundle of His and pacemaker implantation was 
the first non-pharmacological alternative to drug treatment of atrial fibrillation 23. The procedure 
was performed in general anaesthesia, and might be complicated by serious ventricular 
arrhythmias or cardiac rupture. Therefore, a large step forward was taken in 1987 with the use of 
radio  frequency current 24, which gives a more localized and homogeneous tissue necrosis. High 
frequency alternating current does not stimulate pain fibres or neuromuscular end plates, so 
treatment could be performed in local anaesthesia. 
            AV-node ablation makes the patient pacemaker-dependant. Another argument against 
this treatment is the observation that some patients died suddenly during the first months after 
complete block had been created, both with direct current as well as with radiofrequency 
ablation. It is still unknown whether underlying heart disease caused this, or if the sudden rate 
reduction predisposed to  arrhythmia.  Geelen  and  co-workers  found  an  incidence  of  6% 
ventricular fibrillation or sudden death among 100 patients in whom the pacemaker was 
programmed at a heart rate of 70 or less. However, among the next 135 patients in whom the 
pacemaker during 1-3 months did not allow heart rates below 90, no cases of sudden death were 
found 25. 
             By radiofrequency ablation of the atrioventricular node, excellent rate control is 
achieved. Tachycardiomyopathy may be reversed, and the quality of life and physical fitness 
generally improve. For patients with paroxysmal atrial fibrillation, a dual chamber pacemaker 
with mode switch is recommended. 
            Published experience from the Arrhythmia Centre in Oslo contained 33 patients with 
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atrial arrhythmias, of whom 23 had atrial fibrillation 26. Complete atrioventricular conduction 
block was induced in 30 patients, while in two patients a partial block with satisfactory 
ventricular rate was achieved. The authors claim that irreversible destruction of normal 
conductive tissue must be restricted to patients with severe symptoms in whom other treatment 
strategies were not successful. One should particularly be reluctant to induce AV-block in young 
patients, hoping that the future may bring less mutilating therapy 26. 
Modification of the atrioventricular conduction 
            The ventricular rate in atrial fibrillation may be reduced by radiofrequency ablation in the 
same area as atrioventricular nodal tachycardias are treated, i.e. in the area of the slow pathway. 
This can be achieved without inducing a complete conduction block making the patient 
pacemaker dependant 27. The treatment has been effective also in patients without dual nodal 
pathways. A possible explanation has been that ablation shifts the balance between stimulating 
and inhibiting input to the AV node. 60-70% of the patients achieves satisfactory ventricular rate 
control both at rest and during physical activity  28. However, a little risk of ending up with a 
complete heart block remains, so this treatment should not be chosen in patients for whom a 
pacemaker is completely unacceptable. Some patients continue to have much discomfort, 
possibly because the heart rate still is very irregular although not that fast. Therefore, many 
electrophysiologists prefer to induce complete AV-block and implant a pacemaker primarily. 
Catheter-based compartmentalisation of the atria 
            Great efforts have been done to find a catheter-based technique with similar effect as the 
surgical Maze procedure. The concept again has been to reduce the size of confluent atrial 
myocardium so that multiple reentry circles are not allowed to establish. The first case 
description in this field was based on creating three lines of coagulation necrosis in the right 
atrium (  Fig. 2  )29. However, subsequent experience with purely right-sided procedures has 
shown limited success. 
            Two major challenges have been faced: Where to place the linear lesions to prohibit atrial 
fibrillation 30, and how to secure that continuous transmural lesions have been created. Lesions 
in the left atrium that isolate the pulmonary vein inlets seem to be essential. However, large 
lesions in the left atrium imply a risk of thromboembolic complications. The pioneer JF Swartz 
stopped his efforts in ablating chronic atrial fibrillation after two of his 36 patients developed 
severe cerebrovascular insults. Biatrial ablation is time consuming. Initial experience showed 
total procedure duration approaching 12 hours, fluoroscopy time about 2 hours, and a frequent 
need for repeated sessions. Thus, one may ask whether the treatment is more dangerous than the 
illness. However, Swartz demonstrated that it is possible to achieve sinus rhythm with preserved 
biatrial mechanical function in 80% of the patients30. 
During subsequent Maze surgery in a patient in whom two non-successful attempts had been 
made to perform biatrial linear ablation, severe scarring and reduced function of both the right 
and left atria were found. The radiofrequency lesions were not transmural, and one pulmonary 
vein inlet was occluded by a thrombus 31. 
The group of M Haissaguerre in Bordeaux (France) has particularly studied patients with 
paroxysmal atrial fibrillation. Using biatrial linear lesions in a pattern similar to that of Swartz', 
they report favourable results in 70% of the patients, with considerably less atrial fibrillation and 
less need for antiarrhythmic drugs 32. 
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Radiofrequency ablation of focal atrial fibrillation 
             Atrial   fibrillation   may,   at   least   in   some   patients,   be   induced   by   spontaneous 
depolarizations from a focus located in a pulmonary vein inlet (95%) or at various locations in 
the atrial myocard itself  9. Atrial myocardial fibres have been found in the pulmonary veins as 
far as 5 cm from the inlet. The demonstration of focal atrial fibrillation opens for completely new 
therapeutic strategies, since limited ablation may be curative. 
             To diagnose supraventricular extrasystoles that induce atrial fibrillation, digital 12-
channels Holter-recorders are needed. Radiofrequency ablation of a pulmonary vein inlet is 
performed by transseptal catheterization, and pulmonary venous angiography may be helpful. 
Specialized catheters have been designed to facilitate mapping and ablation of the pulmonary 
vein inlets. M Haissaguerre and co-workers have been pioneers also in this treatment  9. Their 
experience indicate a total success rate without antiarrhythmic drugs around 70%, varying from 
90% if a focus is located in one single pulmonary vein, to 20% if foci are located in all four 
pulmonary veins. Late stenoses of the pulmonary veins occurred in as much as 6% of patients, 
but among the first 150 patients, no specific treatment was needed. These results need to be 
confirmed at other centres. 
            New mapping techniques may be beneficial both for focal pulmonary vein ablation and 
for   biatrial   compartmentalisation   procedures.   Using   electroanatomic   mapping,   a   three-
dimensional   activation   model   of   a   cardiac   chamber   may   be   constructed   by   combining 
conventional   activation   mapping   with   determining   the   catheter   position   relative   to   an 
electromagnetic field ("Carto" system  33). With non-contact mapping, virtual electrograms 
representing more than 3000 locations in a cardiac chamber may be determined simultaneously, 
allowing fast analysis of activation pattern ("Ensite" system 34). 
Pacemaker therapy in atrial fibrillation 
            Patients with sick sinus syndrome may need a pacemaker to prevent severe bradycardia 
with syncope. Atrial fibrillation is a common part of the sick sinus syndrome (tachy-brady-
arrhythmia). By atrial pacing, compared to ventricular pacing, total and cardiovascular mortality 
has been shown to decrease, and there is less thromboembolic complications as well as a reduced 
burden of atrial fibrillation 34,35. 
Atrial pacing prevents long pauses and atrial escape beats, which may trigger atrial fibrillation. 
At the same time atrioventricular synchrony is possible. This is opposite to ventricular pacing, in 
which the atria are controlled by the sinus node, which may function poorly. Long pauses and an 
excessive dispersion of atrial repolarization may be expected. Atrial contraction against closed 
atrioventricular valves (pacemaker syndrome) may also cause atrial dilatation and contribute to 
atrial fibrillation. 
            This effect of atrial pacing to prevent atrial fibrillation is strictly prophylactic. Atrial 
pacing will not convert an attack of atrial fibrillation that has already started, because only a 
limited part of fibrillating atria will be captured. Thus, sinus pauses are the only indication of 
pacemaker therapy, while the effect on atrial fibrillation is secondary. 
Biatrial pacing 
            Daubert and co-workers tried to capture more of the atrial myocardium by stimulating 
both the right and the left atria simultaneously. Left atrial pacing was achieved by an electrode in
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the middle or distal part of the coronary sinus 36. The SYNBIAPACE-study showed a trend 
towards a longer interval free of atrial fibrillation with biatrial compared to ordinary dual 
chamber pacing, but the difference did not reach statistical significance 37. 
Saksena   and   co-workers   performed  multisite   right   atrial   rather   than  biatrial   pacing,  by 
stimulating the high right atrium together with the coronary sinus ostium. Among 15 patients 
who prior to pacemaker implantation had an average of 1.5 episodes of atrial fibrillation per 
week, they found no such episodes during the first three months, when everybody was 
programmed to multisite right atrial pacing. During the next three months 12 patients were 
programmed to ordinary dual chamber pacing (three patients denied re-programming, and were 
excluded from this part of the study), and atrial fibrillation was observed in five patients 38. 
Larger studies and longer observational periods are needed to confirm if pacing of the coronary 
sinus ostium really improves protection against atrial fibrillation. 
Atrial defibrillator 
            Cardioversion of atrial fibrillation by external synchronized direct current shocks has a 
high success rate. Internal defibrillation using catheters inside the heart is possible with lower 
current and even higher success rate. Due to the good results with implanted defibrillators for 
ventricular arrhythmia, one has also been interested in implantable defibrillators for paroxysmal 
atrial fibrillation 39. 
A pure atrial defibrillator was available in 1998. Three electrodes were placed in the high right 
atrium,   coronary   sinus   and   right   ventricle,   respectively.   Diagnosis   of   supraventricular 
arrhythmias was based on complex algorithms comparing heart rate and timing of electrical 
activity at the three electrodes. The shock was delivered between the two atrial electrodes. 
A study of 51 patients followed during eight months showed that 96% of 227 episodes of atrial 
fibrillation were successfully converted. In 27% of the episodes, several shocks were necessary 
due to early relapses. No ventricular arrhythmia was elicited by the defibrillations 40. This pure 
atrial defibrillator was, however, withdrawn from the market because the manufacturing 
company was bought. The new owners have signalled that they rather prefer a dual chamber 
defibrillator that is able to deliver low energy cardioversion in case of atrial fibrillation, but with 
the opportunity to deliver high energy shocks if ventricular arrhythmia should appear. Such a 
combined defibrillator is also available from another company. 
Table 3: Therapeutic goals for non-pharmacological treatment of atrial fibrillation
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            The main argument against the atrial defibrillator, except that it is expensive, is that the 
patients feel the shock as painful. Some patients prefer hospitalisation and sedation prior to 
cardioversion, and then one may ask if anything really is gained by having the implanted atrial 
defibrillator. This treatment may, however, be useful for some patients with paroxysmal atrial 
fibrillation who do not have too frequent attacks (about one per month?), but with severe 
symptoms.   It   has   been   hypothesized   that   early   defibrillation   may   prevent   the 
electrophysiological remodelling and thereby inhibit the progression from paroxysmal to 
permanent atrial fibrillation 41 . 
Conclusion 
            Non-pharmacological treatment of atrial fibrillation may be an alternative or supplement 
to drug therapy. Except for atrial pacing in patients with sick sinus syndrome and radiofrequency 
ablation of the atrioventricular node, all non-pharmacological treatments of atrial fibrillation are 
still considered as experimental. Some centres report excellent results with Maze surgery, while I 
doubt if catheter-based biatrial compartmentalisation will ever be a common treatment option. 
Focal ablation in the pulmonary veins is an exciting, new concept, but the results await 
confirmation from several centres. Atrial defibrillators may be a good option for selected patients 
who tolerate the shock. Future will show if it is possible to combine several of these therapeutic 
modalities, for example focal ablation and biatrial pacing, to increase the therapeutic success and 
reduce the risk of complications. 
†Reprinted with permission from: Tidsskr Nor Laegeforen 2000; 120: 2884-9  (Original 
article in Norwegian)
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